AIM ImmunoTech Inc. (AIM) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, AIM ImmunoTech reported revenue of $88,000, down 48.2% from $170,000 the year before. Net income was -$14.0M (a -15861.4% net margin), or -$8.62 per diluted share. Gross margin was -13254.5% and operating margin was -13254.5%. Operating activities generated -$11.0M of cash, leaving -$11.0M of free cash flow. At fiscal year end, AIM ImmunoTech held $5.8M in total assets against $15.6M in total liabilities, including $3.0M of cash and equivalents.
Open the full interactive AIM ImmunoTech financials → Quarterly statements, key ratios, valuation history and price charts.
AIM ImmunoTech Key Stats
| Share Price | $0.17 |
|---|---|
| Market Cap | $2.9M |
| Revenue YoY Growth | -48.2% |
| 52-Week Range | $0.17 – $2.68 |
| Shares Outstanding | 17.1 million (basic, 2026 Q2) |
AIM ImmunoTech Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $163,000 | $135,000 | $141,000 | $202,000 | $170,000 | $88,000 |
| Cost of Goods Sold | $15.3M | $19.0M | — | $32.1M | $19.9M | $11.8M |
| Gross Profit | -$15.2M | -$18.8M | — | -$31.9M | -$19.8M | -$11.7M |
| Operating Income | -$15.2M | -$18.8M | -$19.9M | -$31.9M | -$19.8M | -$11.7M |
| Pre-Tax Income | -$14.4M | -$19.1M | -$19.4M | -$29.0M | -$17.3M | -$14.0M |
| Net Income | -$14.4M | -$19.1M | -$19.4M | -$29.0M | -$17.3M | -$14.0M |
| Diluted EPS | -$45.00 | -$40.00 | — | -$60.00 | -$31.00 | -$8.62 |
AIM ImmunoTech Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $26,000 | $21,000 | $22,000 | $26,000 |
| Net Income | -$3.3M | -$4.2M | -$3.0M | -$3.8M |
| Diluted EPS | $1.57 | -$2.58 | -$0.69 | -$0.43 |
AIM ImmunoTech Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $38.5M | $32.1M | $27.1M | $5.4M | $1.7M | $3.0M |
| Current Assets | $40.3M | $50.2M | $36.3M | $14.6M | $4.2M | $3.3M |
| Total Assets | $64.6M | $57.7M | $40.5M | $19.4M | $8.6M | $5.8M |
| Current Liabilities | $1.1M | $673,000 | $1.4M | $8.7M | $9.5M | $6.2M |
| Total Long-Term Debt | $2.1M | — | — | — | $2.8M | $4.5M |
| Total Liabilities | $3.3M | $820,000 | $2.0M | $9.1M | $9.9M | $15.6M |
| Shareholders' Equity | $61.3M | $56.9M | $38.5M | $10.2M | -$1.3M | -$9.8M |
AIM ImmunoTech Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$10.4M | -$14.0M | -$16.1M | -$21.3M | -$14.9M | -$11.0M |
| Cash From Investing | -$9.2M | -$631,000 | $11.0M | -$832,000 | $4.7M | $1.9M |
| Cash From Financing | $56.6M | $8.2M | $80,000 | $485,000 | $6.4M | $10.4M |
| Free Cash Flow | -$10.4M | -$14.0M | -$16.2M | -$21.4M | -$14.9M | -$11.0M |
Figures from AIM ImmunoTech's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full AIM ImmunoTech financials page for every line item.
AIM ImmunoTech Company Profile
| Ticker | AIM |
|---|---|
| Exchange | NYSE |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Ocala, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000946644 |
Frequently Asked Questions
What was AIM ImmunoTech's revenue in fiscal 2025?
AIM ImmunoTech (AIM) reported revenue of $88,000 for fiscal 2025.
What is AIM ImmunoTech's annual revenue history?
AIM ImmunoTech's annual revenue by fiscal year: 2020: $163,000; 2021: $135,000; 2022: $141,000; 2023: $202,000; 2024: $170,000; 2025: $88,000.
What was AIM ImmunoTech's net income in fiscal 2025?
AIM ImmunoTech reported net income of -$14.0M for fiscal 2025.
What was AIM ImmunoTech's earnings per share (EPS) in fiscal 2025?
AIM ImmunoTech's diluted EPS was -$8.62 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did AIM ImmunoTech generate in fiscal 2025?
AIM ImmunoTech generated -$11.0M of free cash flow in fiscal 2025.
What was AIM ImmunoTech's revenue last quarter?
In its most recent reported quarter (2026 Q2), AIM ImmunoTech reported revenue of $26,000.
How much debt does AIM ImmunoTech have?
AIM ImmunoTech reported $4.5M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of AIM ImmunoTech are outstanding?
AIM ImmunoTech reported a weighted average of 17.1 million basic shares outstanding in 2026 Q2.
What is AIM ImmunoTech's market cap?
Based on its latest closing price, AIM ImmunoTech (AIM) has a market capitalization of about $2.9M.
When does AIM ImmunoTech's fiscal year end?
AIM ImmunoTech's fiscal year end, as registered with the SEC, is December 31.
Where is AIM ImmunoTech headquartered?
AIM ImmunoTech lists its business address in Ocala, Florida in its SEC filings.
AIM ImmunoTech Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →